Mirko Bouda

516 total citations
21 papers, 396 citations indexed

About

Mirko Bouda is a scholar working on Epidemiology, Psychiatry and Mental health and Transplantation. According to data from OpenAlex, Mirko Bouda has authored 21 papers receiving a total of 396 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Epidemiology, 8 papers in Psychiatry and Mental health and 7 papers in Transplantation. Recurrent topics in Mirko Bouda's work include Cytomegalovirus and herpesvirus research (16 papers), Herpesvirus Infections and Treatments (10 papers) and Neurological Complications and Syndromes (8 papers). Mirko Bouda is often cited by papers focused on Cytomegalovirus and herpesvirus research (16 papers), Herpesvirus Infections and Treatments (10 papers) and Neurological Complications and Syndromes (8 papers). Mirko Bouda collaborates with scholars based in Czechia and United Kingdom. Mirko Bouda's co-authors include Tomáš Reischig, Pavel Jindra, Ondřej Hes, Vladislav Třeška, Martin Kacer, Daniel Lysák, Stanislav Kormunda, Ondřej Viklický, K Opatrný and Miroslava Švecová and has published in prestigious journals such as Journal of the American Society of Nephrology, Transplantation and American Journal of Transplantation.

In The Last Decade

Mirko Bouda

21 papers receiving 395 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mirko Bouda Czechia 13 338 125 116 107 85 21 396
Dushyanthi Vimalachandra Australia 6 303 0.9× 55 0.4× 68 0.6× 47 0.4× 56 0.7× 6 440
Laila Almeida Viana Brazil 12 131 0.4× 83 0.7× 41 0.4× 138 1.3× 93 1.1× 43 333
Javier Paúl Spain 11 108 0.3× 72 0.6× 29 0.3× 212 2.0× 87 1.0× 17 341
Jeff Zaltzman Canada 7 56 0.2× 18 0.1× 89 0.8× 83 0.8× 103 1.2× 10 300
Gabriel Bernal Spain 9 154 0.5× 20 0.2× 39 0.3× 174 1.6× 49 0.6× 17 351
Vera Aparecida dos Santos Brazil 6 240 0.7× 17 0.1× 48 0.4× 31 0.3× 42 0.5× 6 273
Martin Kacer Czechia 9 118 0.3× 34 0.3× 68 0.6× 52 0.5× 79 0.9× 13 295
K. Jackson Canada 9 207 0.6× 7 0.1× 51 0.4× 72 0.7× 39 0.5× 24 362
T. Astor United States 6 192 0.6× 15 0.1× 41 0.4× 62 0.6× 50 0.6× 12 382
Margaret J. Gorensek United States 8 155 0.5× 12 0.1× 25 0.2× 17 0.2× 59 0.7× 14 306

Countries citing papers authored by Mirko Bouda

Since Specialization
Citations

This map shows the geographic impact of Mirko Bouda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mirko Bouda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mirko Bouda more than expected).

Fields of papers citing papers by Mirko Bouda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mirko Bouda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mirko Bouda. The network helps show where Mirko Bouda may publish in the future.

Co-authorship network of co-authors of Mirko Bouda

This figure shows the co-authorship network connecting the top 25 collaborators of Mirko Bouda. A scholar is included among the top collaborators of Mirko Bouda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mirko Bouda. Mirko Bouda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Reischig, Tomáš, Martin Kacer, Kristýna Pivovarčíková, et al.. (2023). A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients. Journal of the American Society of Nephrology. 34(5). 920–934. 12 indexed citations
2.
Reischig, Tomáš, Martin Kacer, Ondřej Hes, et al.. (2019). Cytomegalovirus prevention strategies and the risk of BK polyomavirus viremia and nephropathy. American Journal of Transplantation. 19(9). 2457–2467. 26 indexed citations
3.
Reischig, Tomáš, Martin Kacer, Ondřej Hes, et al.. (2019). Viral load and duration of BK polyomavirus viraemia determine renal graft fibrosis progression: histologic evaluation of late protocol biopsies. Nephrology Dialysis Transplantation. 34(11). 1970–1978. 16 indexed citations
4.
Reischig, Tomáš, Martin Kacer, Petra Hrubá, et al.. (2018). Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial. BMC Infectious Diseases. 18(1). 573–573. 17 indexed citations
5.
Reischig, Tomáš, Martin Kacer, Petra Hrubá, et al.. (2016). The Impact of Viral Load and Time to Onset of Cytomegalovirus Replication on Long-Term Graft Survival after Kidney Transplantation. Antiviral Therapy. 22(6). 503–513. 28 indexed citations
6.
Kacer, Martin, Lukáš Kielberger, Mirko Bouda, & Tomáš Reischig. (2015). Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective. Transplant Infectious Disease. 17(3). 334–341. 12 indexed citations
7.
Reischig, Tomáš, Martin Kacer, Pavel Jindra, et al.. (2014). Randomized Trial of Valganciclovir Versus Valacyclovir Prophylaxis for Prevention of Cytomegalovirus in Renal Transplantation. Clinical Journal of the American Society of Nephrology. 10(2). 294–304. 31 indexed citations
8.
Kacer, Martin, Lukáš Kielberger, Mirko Bouda, & Tomáš Reischig. (2014). Pharmacoeconomic Impact of Valganciclovir Versus Valacyclovir for Cytomegalovirus Prophylaxis in Renal Transplant Recipients: A Randomized Controlled Trial.. Transplantation. 98. 763–763. 2 indexed citations
9.
Kielberger, Lukáš, Mirko Bouda, Pavel Jindra, & Tomáš Reischig. (2012). Pharmacoeconomic Impact of Different Regimens to Prevent Cytomegalovirus Infection in Renal Transplant Recipients. Kidney & Blood Pressure Research. 35(6). 407–416. 15 indexed citations
10.
Reischig, Tomáš, Petra Hřibová, Pavel Jindra, et al.. (2012). Long-Term Outcomes of Pre-emptive Valganciclovir Compared with Valacyclovir Prophylaxis for Prevention of Cytomegalovirus in Renal Transplantation. Journal of the American Society of Nephrology. 23(9). 1588–1597. 56 indexed citations
11.
Reischig, Tomáš, Pavel Jindra, Ondřej Hes, Daniel Lysák, & Mirko Bouda. (2012). The 2VAL Study: Randomized Comparison of Valganciclovir Vs. Valacyclovir for Cytomegalovirus Prophylaxis after Renal Transplantation. Transplantation. 94(10S). 541–541. 1 indexed citations
12.
Reischig, Tomáš, Jana Němcová, Tomáš Vaněček, et al.. (2010). Intragraft Cytomegalovirus Infection: A Randomized Trial of Valacyclovir Prophylaxis versus Pre-Emptive Therapy in Renal Transplant Recipients. Antiviral Therapy. 15(1). 23–30. 21 indexed citations
13.
14.
Reischig, Tomáš, Jana Němcová, Tomáš Vaněček, et al.. (2008). PREEMPTIVE VALGANCICLOVIR THERAPY IS NOT ASSOCIATED WITH INCREASE IN CYTOMEGALOVIRUS (CMV) DNA IN RENAL ALLOGRAFT BIOPSY SPECIMENS COMPARED WITH VALACYCLOVIR PROPHYLAXIS. Transplantation. 86(2S). 131–132. 4 indexed citations
15.
Reischig, Tomáš, K Opatrný, Mirko Bouda, et al.. (2002). A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation. Transplant International. 15(12). 615–622. 25 indexed citations
16.
Reischig, Tomáš, K Opatrný, Mirko Bouda, et al.. (2002). A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation. Transplant International. 15(12). 615–622. 27 indexed citations
17.
Reischig, Tomáš, et al.. (2001). Management of acute necrotizing pancreatitis after renal transplantation. Transplantation Proceedings. 33(1-2). 2020–2023. 1 indexed citations
18.
Opatrný, K, et al.. (1997). A Clinical Study to Assess the Effect of Heparin in Dialyzer Rinsing Solutions. The International Journal of Artificial Organs. 20(2). 112–118. 17 indexed citations
19.
Eiselt, Jaromír, et al.. (1996). [The effect of acetate-free biofiltration on anemia and use of erythropoietin].. PubMed. 135(16). 525–9. 1 indexed citations
20.
Bouda, Mirko, et al.. (1994). [Zinc deficiency as a cause of dermatosis in a patient with type I diabetes and renal insufficiency].. PubMed. 40(7). 445–7. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dushyanthi Vimalachandra Breakdown of academic impact, for papers by Laila Almeida Viana Breakdown of academic impact, for papers by Javier Paúl Breakdown of academic impact, for papers by Jeff Zaltzman Breakdown of academic impact, for papers by Gabriel Bernal Breakdown of academic impact, for papers by Vera Aparecida dos Santos Breakdown of academic impact, for papers by Martin Kacer Breakdown of academic impact, for papers by K. Jackson Breakdown of academic impact, for papers by T. Astor Breakdown of academic impact, for papers by Margaret J. Gorensek
Rankless by CCL
2026